Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
NCT01786538
·
clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Regorafenib/FOLFOX
DRUG:
Placebo/FOLFOX
Sponsor
Asan Medical Center